Can lowering #uricacid improve hepatic fibrosis? Dr Naomi Schlesinger presented data from pegloticase #gout studies showing improvement/prevention of worsening vs pbo via the Fib-4 score Changes esp marked in pts with clinically important baseline Fib-4 score @RheumNow #ACR2019 https://t.co/8QUZvlcf57

PATCH: HCQ reduces congenital heart block (CHB) recurrence in babies born to Ro+ mothers w/ sibilings w/ CHB. This is encouraging data that further supports treatment induction in Ro+ pregnant pts to decrease fetal risk. https://t.co/0uU1zZP80l Plenary abs#1761 #ACR19 @RheumNow

• The Prospective Open Label Preventive Approach to Congenital Heart Block with H…

“It’s so rare that a lupus clinical trial makes it to a plenary session...so cherish the moment!” -Dr Richard Furie on anifrolumab in SLE 🤣 #ACR19 @RheumNow

TULIP1 Anifrolumab RCT in SLE Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS) Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6) Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed. #ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz

Neonatal complete heart block is one to avoid. In Ro-pos mothers with a prev child with CHB, HCQ reduces rates from a historic 20% to 7.4% in the PATCH study. It seems we’re yet to fully realize the power of HCQ in conditions like these! @nyuschoolofmed #ACR19 ABST1761 @RheumNow https://t.co/TMzmq6TjJx

#ACR19 @Rheumnow ABS1217 pegadricase (0.2 mg/kg) +ImmTOR (0.15 mg/kg) selected for HtoH study of SEL-212 vs pegloticase based on Ph2T result showing addition of ImmTOR at ≥0.1 mg/kg ⬇️ ADA formation & 66% of pts maintained sUA levels < 6 mg/dL at Wk20.

Loving the aesthetics of the #ACR19 conference center this year. @RheumNow https://t.co/MOZgNDlfzw

HOPE results: 6 week tapering treatment with po prednisolone in HOA pts improved VAS scores and US synovitis. Will this change the way you approach HOA? https://t.co/0MtW7esExU Plenary abs#1760 #ACR19 @RheumNow https://t.co/U5SStHuJoh

• Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Ost…

Over the last 10 years racial and ethnic minorities are significantly underrepresented in rheumatoid arthritis clinical trials with no hope for improvement in the future. How applicable are these results when they do not reflect the population? #ACR19 abstract# 1160 https://t.co/WNSGfyCSKu

RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.

#acr19 @rheumnow FDA notes w/Rheum Meds: 1. ⬇️apremilast dose in Apremilast to 30 mg/d for pt with severe CKD 2. Ok to use RTX in kids 2+ years old 3. Maintenance RTX 500 mg x2 the 500 mg q6mo x18 mo after induction Rx for GPA/MPA (kids use 250 mg/m2 dose then 250 mg/m2 q6 mo

Abstr#1758: In pts with MSK symptoms and +antiCCP, those at high risk of developing RA had tenosynovitis, higher levels of IL-6 and ACPAs. #ACR2019 @RheumNow #RA #rheumatoidarthritis

Some hand OA patients with an inflammatory phenotype have structural benefit from lower dose MTX (but no difference with pain or function, but no difference with adverse events). Why the disconnect? And what’s a rheumatologist to do? Nice, France #ACR19 ABST1759 @RheumNow https://t.co/4SvWzps9DU

The neutrophil nets take the win with nemaline rod myopathy which an be associated with congenital abnormality or HIV. Knowledge Bowl #ACRbest #ACR19 @RheumNow https://t.co/oIhWrcDUP5

Great discussion on OA today at the Plenary session. #ACR19 @RheumNow What would you try in your erosive OA patients who have failed conservative therapy (hand therapy, analgesics and NSAIDs)?